Expression and regulation of osteoprotegerin in adipose tissue

Yonsei Medical Journal

Volumn 48, Issue 5, 2007, Pages 765-772

  An, Juan Ji ^a   Han, Dong He ^a   Kim, Dol Mi ^a   Kim, Se Hwa ^a   Rhee, Yumie ^a   Lee, Eun Jig ^a   Lim, Sung Kil ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Anti angiogenic effects; Obesity; Osteoprotegerin; Receptor activator of NF B ligand

Indexed keywords

COMPLEMENTARY DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTEGRASE; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL CALCIFICATION; BROWN ADIPOSE TISSUE; CELL DIFFERENTIATION; CELL SECRETION; CELL STRAIN 3T3; CONTROLLED STUDY; DRUG ACTIVITY; EPIDIDYMIS; GENETIC TRANSFECTION; INTIMA; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PROTEIN EXPRESSION; PROTEIN SECRETION; TUNICA MEDIA; WHITE ADIPOSE TISSUE;

3T3-L1 CELLS; ADIPOCYTES; ADIPOGENESIS; ADIPOSE TISSUE; ANIMALS; CELL DIFFERENTIATION; GENE EXPRESSION REGULATION; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MICE; OSTEOPROTEGERIN; RANK LIGAND; RATS; RATS, SPRAGUE-DAWLEY; THIAZOLIDINEDIONES; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 36249015353     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2007.48.5.765     Document Type: Article

References (26)

1. Lacey DL, Timms, E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76.
2. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19.
3. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998;12:1260-8.
4. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998;273.14363-7.
5. Malyankar UM, Scatena M, Suchland KL, Yun TJ, Clark EA, Giachelli CM. Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa. B-dependent survival factor for endothelial cells. J Biol Chem 2000;275:20959-62.
6. Collin-Osdoby P, Rothe L, Anderson F, Nelson M, Maloney W, Osdoby P. Receptor activator of-NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem 2001;276:20659-72.
7. Sattler AM, Schoppet M, Schaefer JR, Hofbauer LC. Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. Calcif Tissue Int 2003;74:103-6.
8. Min JK, Kim YM, Kim YM, Kim EC, Gho YS, Kang IJ, et al. Vascular endothelial growth factor up-regulates expression of receptor activator of NF-kappa B (RANK) in endothelial cells. Concomitant increase of angiogenic responses to RANK ligand. J Biol Chem 2003;278:39548-57.
9. Price PA, June AH, Buckley JR, Williamson MK. Osteoprotegerin inhibits artery calcification induced by warfarin and by-vitamin D. Arterioscler Thromb Vasc Biol 2001;21:1610-6.
10. Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly, women. J Clin Endocrinol Metab 2001;86:631-7.
11. Schoppet M, Sattler AM, Schaefer JR, Herzum M, Maisch B, Hofbauer LC. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab-2003;88:1024-8.
12. Jono S, Ikari Y, Shioi A, Mori K, Miki T, Hara K, et al. Serum osteoprotegerin levels are associate with the presence and severity of coronary artery disease. Circulation 2002;106:1192-4.
13. Schoppet M, Schaefer JR, Hofbauer LC. Low serum levels of soluble RANK ligand are associated with the presence of coronary artery disease in men. Circulation 2003;107:e76.
14. Rasmussen LM, Ledet T. Osteoprotegerin and diabetic macroangiopathy. Horm Metab Res 2005;37 Suppl 1: 90-4.
15. Imhof BA, Aurrand-Lions M. Angiogenesis and inflammation face off. Nat Med 2006;12:171-2.
16. Nakashima T, Kobayashi Y, Yamasaki S, Kawakami A, Eguchi K, Sasaki H, et al. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappa B ligand: modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun 2000;275:768-75.
17. Collin-Osdoby P, Rothe L, Anderson F, Nelson M, Maloney W, Osdoby P. Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem 2001;276:20659-72.
18. Rupnick MA, Panigrahy D, Zhang CY, Dallabrida SM, Lowell BB, Langer R, et al. Adipose tissue mass can be regulated through the vasculature. Proc Natl Acad Sci U S A 2002;99:10730-5.
19. Hausman GJ, Richardson RL. Adipose tissue angiogenesis. J Anim. Sci 2004;82-925-34.
20. Groth AC, Olivares EC, Thyagarajan B, Calos MP. A phage integrase directs efficient site-specific integration in human cells. Proc Natl Acad Sci U S A 2000;97:5995-6000.
21. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/ RANKL/RANK system for bone and vascular diseases. JAMA 2004;292:490-5.
22. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004;92:347-55.
23. Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKI, and osteoprotegerin. Circ Res 2004;95:1046-57.
24. Pantouli E, Boehm MM, Koka S. Inflammatory cytokines activate p38 MAPK to induce osteoprotegerin synthesis by MG-63 cells. Biochem Biophys Res Commun 2005;329:224-9.
25. Xu H, Barnes GT, Yang Q Tan G, Yang D, Chou CJ, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003;112-1821-30.
26. Olesen P, Ledet T, Rasmussen LM. Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha. Diabetologia 2005;48:561-8.